Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively (Q82223915)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 December 2009

Language	Label	Description	Also known as
English	Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively	scientific article published on 14 December 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

author name string

A Meddeb-Garnaoui

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A Toumi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H Ghelis

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Mahjoub

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H Louzir

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Chenik

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

14 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1881-1886

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Zoonotic cutaneous leishmaniasis in central Tunisia: spatio temporal dynamics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

The immunology of susceptibility and resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Immunopathology of leishmaniasis: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

T-cell response in human leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Development and application of 'simple' diagnostic tools for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

rK39: A Cloned Antigen of Leishmania chagasi that Predicts Active Visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Evolutionarily conserved proteins as prominent immunogens during Leishmania infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Characterization of the immune response to Leishmania infantum recombinant antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.075

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.11.075

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20005858%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82223915&oldid=2136867753"